基金经理：赵宗庭
| 单位净值:0.4628 | 净值增长率:3.26% | 累计净值:0.4628 | 截止日期:2024/5/9 | ||
|---|---|---|---|---|---|
| 最新估值:-(-) | 涨跌幅:- | 涨跌额:- | |||
| 最新规模:26.25亿元 | 风险等级:中等风险 | 申购状态:可申购 | 赎回状态:可赎回 |
展开全部
- 基本资料
- 投资风格
- 基金财务状况
- 基金评级
华夏恒生香港上市生物科技ETF(QDII)(159892)申购赎回 |
||||||
|---|---|---|---|---|---|---|
| 报告期 | 期初总份额(份) | 期末总份额(份) | 期间总申购份额(份) | 期间总赎回份额(份) | 期间净申赎份额(份) | 净申赎比例 |
| 2024/3/31 | 5,177,270,000 | 5,672,270,000 | 575,000,000 | 80,000,000 | 495,000,000 | 9.56% |
| 2023/12/31 | 760,266,000 | 5,177,270,000 | 4,576,000,000 | 159,000,000 | 4,417,000,000 | 580.98% |
| 2023/12/31 | 3,825,270,000 | 5,177,270,000 | 1,376,000,000 | 24,000,000 | 1,352,000,000 | 35.34% |
| 2023/9/30 | 2,138,270,000 | 3,825,270,000 | 1,722,000,000 | 35,000,000 | 1,687,000,000 | 78.9% |
| 2023/6/30 | 760,266,000 | 2,138,270,000 | 1,478,000,000 | 100,000,000 | 1,378,000,000 | 181.25% |
| 2023/6/30 | 1,229,270,000 | 2,138,270,000 | 929,000,000 | 20,000,000 | 909,000,000 | 73.95% |
| 2023/3/31 | 760,266,000 | 1,229,270,000 | 549,000,000 | 80,000,000 | 469,000,000 | 61.69% |
| 2022/12/31 | 161,266,000 | 760,266,000 | 611,000,000 | 12,000,000 | 599,000,000 | 371.44% |
| 2022/12/31 | 298,266,000 | 760,266,000 | 465,000,000 | 3,000,000 | 462,000,000 | 154.9% |
| 2022/9/30 | 243,266,000 | 298,266,000 | 55,000,000 | 0 | 55,000,000 | 22.61% |
| 2022/6/30 | 161,266,000 | 243,266,000 | 91,000,000 | 9,000,000 | 82,000,000 | 50.85% |
| 2022/6/30 | 243,266,000 | 243,266,000 | 9,000,000 | 9,000,000 | 0 | 0% |
| 2022/3/31 | 161,266,000 | 243,266,000 | 82,000,000 | 0 | 82,000,000 | 50.85% |
| 2021/12/31 | 239,266,000 | 161,266,000 | 71,000,000 | 149,000,000 | -78,000,000 | -32.6% |
| 2021/12/31 | 239,266,000 | 161,266,000 | 71,000,000 | 149,000,000 | -78,000,000 | -32.6% |
*注：新浪财经提醒：以上数据由合作伙伴提供，仅供参考，交易请以正式公告数据为准。